Esophageal Cancer
Conditions
Interventions
Observation group (including 1. Surgery group: Patients who received surgery as the main treatment method
2. Chemotherapy group: Patients who received chemotherapy as the main treatment mode
3. Radiotherapy group: patients who received radiotherapy as the main treatment method
4. Comprehensive treatment group: patients who received combined treatment of multiple treatment methods.):None
Sponsors
Meishan City People's Hospital
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Inclusion Criteria: Age >=40 and =4 cycles of platinum-based chemotherapy. Radiotherapy group: Received radical radiotherapy (dose >=50 Gy). Multimodality group: Completed neoadjuvant therapy followed by surgery, or concurrent chemoradiotherapy. 3.Data Integrity: Complete baseline data (including imaging reports for TNM staging). At least 1 year of regular follow-up (outpatient/telephone).
Exclusion criteria
Exclusion criteria: 1.Clinical Characteristics: History of other malignant tumors. Severe cardiac dysfunction (NYHA Class III–IV) or hepatic/renal insufficiency (Child-Pugh Grade C). 2.Treatment-Related: Received palliative treatment or non-standard regimens. Treatment interruption (chemotherapy 30% (e.g., staging, treatment regimen). Lost to follow-up or incomplete follow-up data. Concurrent participation in other interventional clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival;Disease-Free Survival;Local Control Rate;Postoperative Recovery Duration;Hospital Stay Duration;Incidence of Adverse Events (including anastomotic leakage, pulmonary infection, incisional infection, etc.);Chemotherapy-Related Adverse Effects (including myelosuppression, nausea and vomiting, alopecia, etc.);Radiotherapy-Related Adverse Effects (including esophageal perforation, radiation pneumonitis, etc.); | — |
Countries
China
Contacts
Public ContactShi Yong
Meishan City People's Hospital
Outcome results
None listed